Slide 1: Dong-A Pharmaceutical 2Q 2012 Performance Results
Dong-A Pharmaceutical 2Q 2012 Performance Results JULY 2012 All of us at Dong-A are dedicated to building a heathier society for humanity. This philosophy encompasses the health and welt being of humankind as a whole as well as the environment and the vomy. Committed to building vealihier aociety al
Slide 2: Forward Looking Statements
Forward Looking Statements The business results for the 2nd quarter of 2012, currently under audit review, are presented here for investors’ convenience. Hence, please be advised that some of their contents may be altered in the course of audit. This presentation may contain “forward-looking stateme
Slide 3: Table of Contents
Table of Contents I. Financial Performance (K-IFRS Separate) II. Performance by Division III. R&D Update Appendix 2
Slide 4: I. Financial Performance (K-IFRS Separate)
I, FINANCIAL PERFORMANCE (K-IFRS SEPARATE) 3 (%) DONG-A PHARM.
Slide 5: Financial Performance – Sales & OPM
Financial Performance – Sales & OPM YoY QoQ [KRW bil.] [KRW bil.] 13.3% (29.8) 7.4% (16.2) 6.6% (16.2) 6.6% (16.2) 9.8% 12.8% 224.5 246.5 246.5 218.6 2Q '11 2Q '12 1Q '12 2Q '12 Sales OPM * Sales grew 2.5%, YoY if sales from GSK products(KRW16.4bil.) are not considered 4
Slide 6: Financial Performance – Margin Analysis
Financial Performance – Margin Analysis 2Q ‘11 1Q '12 2Q '12 YoY QoQ Cost of Goods Sold Ratio 41.4% 48.9% 50.0% 8.6%p 1.1%p SG&A Expenses 46.4% 44.7% 42.4% -4.0%p -2.3%p HR Related Cost per Sales 14.9% 11.9% 14.3% -0.6%p 2.4%p (Salary + Severance + Fringe Benefit) R&D Cost per Sales 7.8% 11.1% 7.8%
Slide 7: 2012 2Q Balance Sheet
2012 2Q Balance Sheet [KRW bil.] 2012. 03 2012. 06 QoQ Major Financial Ratios Total Asset 1,268.1 1,297.9 2.4% 75.7% 78.3% Liability to Cash 218.6 250.6 14.6% Equity Ratio 47.8% 141.7 143.1 44.9% Receivable 0.9% Debt to Equity Ratio Inventory 127.9 121.3 -5.1% 14.7% 13.4% Net Debt to Total Liability
Slide 8: II. Performance by Division
Il, PERFORMANCE BY DIVISION DONG-A PHARM.
Slide 9: Performance by Division
Performance by Division Sales Portion Sales by division [KRW bil.] Growth Division 2Q ‘11 1Q ‘12 2Q ‘12 YoY QoQ 47.6% 53.9% ■ ETC 120.9 107.7 117.2 -3.1% 8.8% ■ Bacchus 38.7 32.7 49.7 28.5% 52.1% 20.2% ■ OTC 23.5 33.3 36.4 54.5% 9.1% 17.2% 10.5% 14.8% ■ Medical 23.5 20.6 18.0 -23.4% -12.3% 10.5% 7.3
Slide 10: Performance by Division – ETC
Performance by Division – ETC [KRW bil.] -3.1% 8.8% 120.9 117.2 107.7 2Q '11 2Q '12 1Q '12 * Sales dropped 16.1%, YoY if sales from GSK products(KRW16.4bil.) are not considered 9
Slide 11: Performance by Division – ETC: Major Products
Performance by Division – ETC Major ETC Products [KRW bil.] -7.8% 21.9 20.2 -28.9% -18.1% 11.7 11.7 -31.7% 9.6 9.8 -26.6% 8.3 28.8% 5.9% -15.9% 7.0 -31.9% 6.7 6.1 4.8 5.2 5.5 5.1 5.2 5.2 New 4.2 3.5 3.2 0.0 Stillen Plavitor Lipinon Opalmon Growtropin Talion Zydena Orodipine Cozartan Motilitone 2Q '1
Slide 12: Performance by Division – OTC (Bacchus/Other)
Performance by Division – OTC (Bacchus/Other) [KRW bil.] 86.1 38.4% 30.4% 66.0 62.2 36.4 54.5% 9.1% 23.5 33.3 Other OTC Bacchus 49.7 38.7 28.5% 52.1% 32.7 2Q '11 2Q '12 1Q '12 * Sales grew 14.0%, YoY if sales from Bayer & GSK products(KRW9.5bil.) are not considered 11
Slide 13: Performance by Division – OTC: Major Products
Performance by Division – OTC (Bacchus/Other) Major OTC Products [KRW bil.] 17.0% 45.2 38.7 24.3% 76.5% New 14.3% -9.5% 4.5 4.8 5.9 5.7 3.3 3.8 4.4 2.8 2.5 0.0 Bacchus D Bacchus F Panpyrin Garglin Bigen Morning Care 2Q '11 2Q '12 12
Slide 14: Performance by Division – Medical
Performance by Division – Medical [KRW bil.] 23.5 -23.4% 20.6 -12.3% 18.0 12.3 -11.1% 11.0 -1.2% 10.9 Medical Equipment Diagnostics 11.3 -36.7% 9.5 7.1 -25.1% 2Q '11 2Q '12 1Q '12 13
Slide 15: Performance by Division – Medical: Major Products
Performance by Division – Medical Major Medical Equipment Products [KRW bil.] -6.6% 5.1 4.8 -7.9% 2.7 -12.6% 2.5 -29.2% -17.0% 2.1 1.8 1.4 1.4 1.0 1.1 Arificial Joint Blood Vessel Stent Prosthetic Heart Valve Dental Implant Sphygmotonograph (Biomet) (Abbott) (Medtronic) (Biomet) & Surgical Equipment
Slide 16: Performance by Division – Overseas
Performance by Division – Overseas [KRW bil.] 11.9% 80.7% 24.2 21.6 13.4 2Q '11 2Q '12 1Q '12 15
Slide 17: Performance by Division – Major Overseas Products
Performance by Division – Overseas Major Overseas Products [KRW bil.] 38.3% 5.7 128.2% 5.0 11.7% 4.1 3.7 3.3 173.5% 68.7% 2.3 2.2 2.2 1.4 New 1.0 0.8 0.0 Growtropin Cycloserine Terizidone Atorvastatin Zydena Bacchus 2Q '11 2Q '12 16
Slide 18: Performance by Division – Major Overseas Regions
Performance by Division – Overseas Major Overseas Regions [KRW bil.] 38.0% 4.9 304.3% 4.1 11.8% 3.6 3.1 404.1% 2.8 160.8% 2.7 2.4 89.0% 1.6 New 1.0 1.0 0.9 0.8 0.5 0.0 Brazil India Cambodia Japan S. Africa Russia Turkey 2Q '11 2Q '12 17
Slide 19: III. R&D Update
Ill, R&D UPDATE DONG-A PHARM.
Slide 20: R&D Pipeline – NCE (New Chemical Entity)
R&D Pipeline – NCE (New Chemical Entity) TYPE CODE NAME MAJOR INDICATION DESCRIPTION STAGE Phase 3 completed (US) Erectile Dysfunction Warner Chilcott Benign Prostatic Phase 2 planned (JP) Hyperplasia Meiji Seika Pharma. DA – 8159 PDE-5 Inhibitor Under Phase 2 (EU) Portal Hypertension Dr. Falk Pulmo
Slide 21: R&D Pipeline – Phyto & Biopharmaceuticals
R&D Pipeline – 천연물 & 바이오의약품 TYPE CODE NAME MAJOR INDICATION DESCRIPTION STAGE Phyto DA-9801 Diabetic Neuropathy Herbal Extracts Under Phase 2 (KR) DA-3801 Infertility (Ovulation Induction) Recombinant FSH Under Phase 3 (KR) DA-3803 Infertility Recombinant hCG Under Phase 3 (KR) DA-3030 Diabetic Neur
Slide 22: R&D Pipeline – Other Bio-medicine
R&D Pipeline – Other Bio-medicine R&D on Bio at Beginning Stage Biosimilar/better - DA-3811 (Gaucher Disease, Cerezyme Biosimilar) DA-3808 (Hemophilia A, Advate Biosimilar) DA-3880 (Anemia of Chronic Renal Failure, Aranesp Biosimilar) Antibody - DA-3111 (her2 Positive Breast Cancer, Herceptin Bi
Slide 23: R&D Roadmap - NCE/Phyto
R&D Roadmap - NCE/Phyto 2013~2014 2015~2016 2017~ DA-8159* - BPH (US) DA-8159 DA-8159* - PAH (KR) DA-8159* - ED (US) - BPH (JP) DA-6034 DA-6034 - Dry Eye (KR) DA-8159* -Gastritis (KR) - PH (EU) DA-8031 - Premature Ejaculation (KR) DA-6886 DA-7218* - Irritable Bowel Syndrome (KR) - ABSSSI (US) DA-980
Slide 24: R&D Roadmap - Bio
R&D Roadmap - Bio 2013~2014 2015~2016 2017~ DA-3091** - Diabetes (KR) DA-3030 - Diabetic Neuropathy (KR) DA-3031** - Neutropenia (KR) DA-3002 DA-3808 - Idiopathic Short Stature (KR) - Hemophilia (KR) DA-3801 - Ovulation Induction (KR) DA-3051* DA -3111* - Multiple Sclerosis (BR) - her2 Breast Cancer
Slide 25: Appendix
Slide 26: Condensed Statements of Financial Position (Separate)
Condensed Statements of Financial Position (Separate) [KRW bil.] 1Q ‘11 2Q ‘11 3Q ’11 4Q ‘11 1Q ‘12 2Q ‘12 Total Assets 1,137.8 1,150.7 1,195.0 1,236.8 1,268.1 1,297.9 Current Assets 403.4 416.1 458.9 466.2 496.7 524.5 Cash & Equivalents 146.8 144.4 198.3 194.6 218.6 250.6 Receivables 131.9 140.1 14
Slide 27: Condensed Statements of Income (Separate)
Condensed Statements of Income (Separate) [KRW bil.] 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 2011 1Q ‘12 2Q ‘12 Sales 210.2 224.5 241.9 230.7 907.3 218.6 246.5 COGS 82.3 93.0 113.7 114.2 403.3 106.9 123.3 Gross Profit 128.0 131.5 128.2 116.4 504.0 111.7 123.1 SG&A 99.9 104.1 98.8 102.4 405.2 97.6 104.4 Other In
Slide 28: Performance by Division
Performance by Division [KRW bil.] Division 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 2011 1Q ‘12 2Q ‘12 ETC Total 114.5 120.9 135.9 125.1 496.5 107.7 117.2 OTC Total 51.9 62.2 70.7 68.0 252.9 66.0 86.1 Bacchus 26.6 38.7 46.7 38.2 150.1 32.7 49.7 Other OTC 25.3 23.5 24.0 29.8 102.7 33.3 36.4 Medical Total 25.2 23
Slide 29: Major Products Sales (ETC)
Major Products Sales (ETC) [KRW bil.] Product 1Q ‘11 2Q ‘11 3Q ‘11 4Q ’11 2011 1Q ‘12 2Q ‘12 Stillen 22.1 21.9 21.0 23.2 88.1 21.0 20.2 Lipinon 11.5 11.7 11.3 11.5 46.0 7.7 9.6 Plavitor 10.5 11.7 10.5 11.4 44.2 8.2 8.3 Opalmon 8.9 9.8 9.7 8.7 37.0 6.1 6.7 Orodipine 6.8 7.0 6.1 6.3 26.3 4.9 5.2 Growt
Slide 30: Major Products Sales (OTC)
Major Products Sales (OTC) [KRW bil.] Product 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 2011 1Q ‘12 2Q ‘12 Bacchus 26.6 38.7 46.7 38.2 150.1 32.7 49.7 Panpyrin 6.9 4.8 4.5 6.3 22.4 7.3 5.9 Bigen 3.8 3.8 4.0 3.6 15.4 3.8 4.4 Garglin 3.4 3.3 3.1 3.5 13.3 5.3 5.7 Morning Care 2.8 2.8 2.5 3.3 11.3 2.9 2.5 29
Slide 31: Thank You
THANK YOU